Work

[O2–09–02]: EVALUATION OF SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MEDI1814, A BETA‐AMYLOID 42 (Aβ42)‐SPECIFIC ANTIBODY, IN PATIENTS WITH MILD‐MODERATE ALZHEIMER'S DISEASE

Year: 2017

Type: article

Source: Alzheimer s & Dementia

DOI: 10.1016/j.jalz.2017.07.193

Authors: Thor Ostenfeld, Michael Pomfret, Andy Billinton, Iain Chessell, Tharani Chessell, Eva Lindqvist, Zulma Santisteban Valencia, Maria Groves, Rajesh Narwal, Manasa Tatipalli, Nancy Lee, Richard Turner, Keith Tan, Amanda Dudley

Institutions: AstraZeneca (United Kingdom), AstraZeneca (Sweden)

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2765896553

FWCI: 0.862

Cites:

Cited by: 8

Related to: 10